|

VIS171 Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • Otsuka Pharmaceutical Development & Commercialization, Inc.1

Indications

  • Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)1
  • Alopecia Areata (AA)1
  • Systemic Lupus Erythematosus (SLE)1
  • Lupus1

Other1 trial

A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.